A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

Description

This is a Phase 3 Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

Conditions

Secondary Hyperparathyroidism, Chronic Kidney Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a Phase 3 Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

Phase 3, Randomized, Open-label, Controlled, Multiple Dose, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 Days to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis

A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

Condition
Secondary Hyperparathyroidism
Intervention / Treatment

-

Contacts and Locations

Los Angeles

Childrens Hospital of Los Angeles, Los Angeles, California, United States, 90027

Aurora

Childrens Hospital Colorado, Aurora, Colorado, United States, 80045

Kansas City

Childrens Mercy Hospital, Kansas City, Missouri, United States, 64108

New York

Mount Sinai Kidney Center - B1 Renal Treatment, New York, New York, United States, 10029

Cincinnati

Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States, 45229

Cleveland

Cleveland Clinic Foundation, Cleveland, Ohio, United States, 44195

Oklahoma City

The Childrens Hospital at Oklahoma University Medical Center, Oklahoma City, Oklahoma, United States, 73104

Philadelphia

Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, 19104

Dallas

Childrens Medical Center Dallas, Dallas, Texas, United States, 75390

Salt Lake City

Primary Childrens Hospital Outpatient Services, Salt Lake City, Utah, United States, 84113

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    0 Years to 18 Years

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    Amgen,

    MD, STUDY_DIRECTOR, Amgen

    Study Record Dates

    2026-01-30